The past three years have revealed something unexpected about President Bola Ahmed Tinubu’s ambitious healthcare reforms. While most Nigerians rightly focus on hospital queues, medicine prices, and insurance coverage, a quieter transformation is reshaping the nation’s economic landscape. This reform program, launched in December 2023 under the Nigeria Health Sector Renewal Investment Initiative, is doing more than healing bodies—it’s building industries.
The healthcare sector, long seen as a drain on public funds, is morphing into a productive engine. More than six million Nigerians have joined organized health insurance since 2023, creating a predictable market that investors crave. Over 4,100 primary healthcare centers are being revitalized, with more than 3,100 already operational. These aren’t just health statistics; they’re economic signals.
The Presidential Initiative to Unlock the Healthcare Value Chain has unlocked over $5 billion in investment projects across pharmaceuticals, vaccines, diagnostics, and medical devices. Afreximbank’s $1 billion financing platform and partnerships with the European Investment Bank are flooding the sector with long-term capital. Local manufacturers who once only imported are now building factories. Companies that saw Nigeria as a dumping ground for foreign goods are setting up assembly lines.
This shift matters because every pill produced locally, every syringe manufactured domestically, and every vaccine bottled within Nigeria’s borders keeps economic value at home. The reforms are creating a manufacturing ecosystem that could position Nigeria as a regional health product hub. The Presidential Executive Order on local manufacturing and Medipool’s pooled procurement system are dismantling barriers that once made long-term investment seem risky.
Human capital is getting equal attention. Over 78,000 frontline health workers have been retrained, with a target of 120,000. The National Health Fellowship is cultivating public sector leaders from all 774 local government areas. Instead of panicking over brain drain, the reforms are expanding the pipeline of skilled professionals while improving working conditions. A larger, better-trained workforce doesn’t just improve hospital care—it strengthens the entire economy’s productive capacity.
Scientific capability is also rising. Clinical trial capacity is expanding, genomics investments are boosting disease surveillance, and regulatory reforms are building confidence in Nigerian-made health products. Universities, research institutions, and industry are forging partnerships that shorten the distance between lab discoveries and commercial products.
Healthcare reforms will always be judged by maternal mortality rates and access to medicines. Those metrics remain vital. But the collateral consequences of Tinubu’s reforms—a stronger industrial base, skilled workforce, and growing investment—may ultimately prove more transformative. For a country pursuing a one-trillion-dollar economy, healthcare is no longer just a social sector. It’s becoming a foundation for long-term growth.
Okey Akpa, PhD, is Managing Director of SKG Pharma and President of the West African Pharmaceutical Manufacturers Association.
